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ABSTRACT   
The autosomal dominant trait hereditary haemorrhagic telangiectasia (HHT) affects 1 
in 5-8,000.  Genes mutated in HHT (most commonly for endoglin or ALK-1) encode 
proteins that modulate TGF- superfamily signalling in vascular endothelial cells; 
mutations lead to the development of fragile telangiectatic vessels and arteriovenous 
malformations.  In this article we review the underlying molecular, cellular and 
circulatory pathobiology; explore HHT clinical and genetic diagnostic strategies; 
present detailed considerations regarding screening for asymptomatic visceral 
involvement; and provide overviews of management strategies. 
 
 
 
IN BRIEF  
 Autosomal dominant; 
 Commonly results from mutations in endoglin (HHT1) or ACVRL1 (HHT2); 
 Rarely due to mutations in Smad4, or other genes ; 
 Known disease genes involved in TGF- superfamily signalling; 
 Marked intrafamilial variation; 
 Often only associated with nosebleeds, telangiectasia and a normal life-span; 
 Up to a third of patients have chronic or severe anaemia, with gastrointestinal 
bleeding increasing with age.  
 Asymptomatic arteriovenous malformations occur in pulmonary (~50%), 
hepatic (30%), cerebral (~10%) and spinal (~1%) circulations; 
 Common AVM complications include stroke (ischaemic and haemorrhagic) 
and brain abscess; 
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 Rarer HHT complications include deep venous thromboses; symptomatic liver 
disease requiring liver transplantation; severe pulmonary hypertension; 
pregnancy-related death, and spinovascular accidents; 
 
 
INTRODUCTION 
The vascular disorder hereditary haemorrhagic telangiectasia (HHT) affects 1 in 5-
8,000 
1
 
2
, and is inherited as an autosomal dominant trait. HHT disease-causing genes 
encode proteins that modulate TGF-beta superfamily signalling in vascular endothelial 
cells.  Genetic testing for endoglin (HHT type 1), ALK-1 (HHT type 2) and Smad4 
(HHT in association with juvenile polyposis (JPHT) is available; further genes are 
predicted at loci identified by linkage analyses on chromosomes 5 (HHT3) and 7 
(HHT4) (Table 1).  While HHT predominantly manifests as a heterozygous condition, 
several studies investigating children with two affected parents support in utero or 
infantile homozygous lethality in HHT 
3-5
. 
 
 
HHT gene mutations lead to the development of abnormal vascular structures which 
range from dilated microvessels to large arteriovenous malformations (AVMs) 
measuring several centimeters in diameter (Figure 1). These occur at specific sites in 
systemic and pulmonary circulations (Figure 2).  Fragile walls and turbulent blood 
flow render these vessels more prone to haemorrhage than normal vessels.  However, 
for pulmonary and hepatic AVMs, it is the consequences of arteriovenous shunting 
that lead to most clinical features (Table 2).  Complications commonly occur from 
previously silent AVMs, and complications can be prevented if AVMs are recognised 
 4 
and treated.  Asymptomatic screening and treatment programmes form major 
components of HHT management,.  Useful recent reviews include 
6
 
7
 
8
 
9
. 
 
 
CLINICAL OVERVIEW 
HHT was first described as a familial disease characterised by anaemia, severe 
recurrent nose bleeds, and gastrointestinal blood loss 
15
 
16
.  There was early 
recognition of HHT-affected individuals developing abnormal vascular structures at 
other sites, particularly arteriovenous malformations (AVMs) of the pulmonary 
17
 
hepatic 
18
 and cerebral 
19
 circulations.  The majority of HHT patients will be affected 
by AVMs in at least one of these sites, with AVMs usually remaining silent 
20
.  More 
recently, the HHT disease spectrum has expanded further to encompass pulmonary 
hypertension (two forms predominate in HHT); juvenile polyposis; a prothrombotic 
state; and potential immune dysfunction (see Table 2 for references). 
   
HHT presentation patterns are highly variable even within families.  Spontaneous 
recurrent nose bleeds are the most common and usually earliest clinical manifestation 
of HHT, often commencing pre school age.  Telangiectases of the skin and buccal 
mucosa typically present from about the third decade of life, and increase with age. 
Recurrent haemorrhage from the gastrointestinal tract is a feature of later years in 15-
20% of individuals 
21
.  Major complications of HHT include severe anaemia from 
chronic nasal and gastrointestinal haemorrhage; stroke (ischaemic and brain abscess 
from pulmonary AVMs; haemorrhagic from cerebral AVMs); deep venous 
thromboses, and in rarer cases symptomatic liver disease requiring liver 
transplantation; severe pulmonary hypertension; pregnancy-related death, and 
spinovascular accidents (see Table 2).  Most HHT-affected individuals however will 
not have life-limiting consequences from their HHT 
22
.  Presymptomatic AVM 
 5 
screening programmes highlight that prior to screening, the majority of affected 
individuals are unaware of their HHT diagnosis 
23
.    
 
The goal of HHT management is to optimise the overall outcome of affected 
individuals, without raising excessive alarm about vascular lesions which may be of 
little consequence. Symptomatic patients with active medical problems due to their 
HHT deserve review by informed specialised services. For people with HHT who are 
well, the focus is on education (including recently published recommendations 
regarding dental care and pregnancy management) and presymptomatic screening 
programmes. Exact clinical management regimes differ between countries, 
predominantly due to differing healthcare practices^.   
 
 
MOLECULAR AND GENETIC BASIS OF THE DISEASE  
Mutated genes and new loci 
Three HHT disease-causing genes have been identified to date (Table 2).  HHT type 1 
results from mutations in ENG encoding endoglin
24
(Figure 3A); HHT type 2 from 
mutations in ACVRL1 encoding activin receptor like kinase (ALK1) 
25
(Figure 3B), 
and HHT in association with juvenile polyposis (JPHT) from mutations in MADH4 
26
. 
There are at least two further unidentified genes that can cause classical HHT, HHT3 
mapped to chromosome 5q between D5S2011 and D5S2490 (Figure 3C) and HHT4 
on chromosome 7p between D7S2252 and D7S510 (Figure 3D) 
27,28
. 
 
Distribution and frequency of gene mutations 
The majority of HHT patients (>80%) will have mutations in either ENG or ACVRL,   
ENG mutations being more common (61%) than ACVRL1 mutations (37%) or 
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MADH4 (2%) 
29
. There is a geographical variation, with both North American and 
European series demonstrating either ACVRL1 predominance (US 
30
; European 
31,32
) 
or an ENG bias (US 
33
; European 
34
 
35
).  It is therefore not clear whether this reflects 
the referral practice of HHT centres, or genuine geographical variation.    
 
More than 600 different mutations have been found in ENG or ACVR in HHT families 
(see www.hhtmutation.org).  Neither gene displays a common mutation; and the 
majority of mutations have been reported only once. All types of mutations are found 
in ENG and ACVRL1, including deletions, insertions, missense, nonsense and splice 
site (Figure 3). The JPHT mutations found to date are in the last four exons of Smad4 
(exons 8-11): mutations types include missense, nonsense and frameshift, with a high 
incidence of de novo mutations 
26,29
.   
Genotype phenotype relationships 
Recent large series support early observations, finding pulmonary and cerebral AVMs 
more common in HHT1 (ENG mutations), and hepatic AVMs more common in 
HHT2 (ACVRL1 mutations) 
35
 
34
 
30,33
 
31,32
. Although there was an initial suggestion 
that overall severity of disease is greater in HHT1 than HHT2 
36
, this study predated 
the recognition of pulmonary hypertension, and there was no difference in 90 month 
mortality in a later series 
35
. 
 
Pulmonary hypertension 
37
 (Figure 1B) and juvenile polyposis 
26
 are recognised as 
part of the spectrum of HHT for particular families. As illustrated in Figure 2B, 
pulmonary hypertension is not a single disease entity, and can result from multiple 
secondary causes in HHT.  The pure pulmonary arterial hypertension (PAH) 
phenotype seen in patients with HHT is indistinguishable from PAH in the general 
population due to mutations in the related BMPRII (Figure 4). Juvenile polyposis (JP) 
seen in HHT patients with Smad4 mutations is indistinguishable from JP in the 
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general population most commonly due to mutations in BMPR1A which encodes a 
related protein.  In HHT, pulmonary artery hypertension and JP were initially 
considered attributable solely to ACVRL1 and Smad4 mutations respectively.  There 
are rare reports of both pulmonary artery hypertension and JP associated with ENG 
missense mutations.  Further evaluation is needed to determine whether these 
sequence variations are disease-causing or benign variants.  
 
These genotype-phenotype correlation studies suggest that while normal function of 
the gene products of ENG, ACVRL1 and MADH4 are all required to prevent 
development of an HHT-like phenotype, there are likely to be differences in the 
normal requirements for the three proteins in different vascular beds and cell types. 
  
Biology of the disease  
Phenotypic considerations, expression analysis of mutant endoglin and ALK1 proteins, 
and HHT-like phenotypes in heterozygous mice implicate haploinsufficiency of the 
respective protein as the cause of HHT1 and HHT2 
6,34
. Dominant negative mutations 
in endoglin can be generated but may cause different phenotypes: for example, 
truncated soluble endoglin is associated with the non HHT phenotype of pre-
eclampsia 
38
 
 
The genes mutated in HHT encode proteins involved in transforming growth factor 
(TGF)-β superfamily signalling; perturbation of this signalling pathways is therefore 
implicated in the pathogenesis of HHT.  Superfamily ligands such as TGF-βs, BMPs, 
activins, nodals, GDFs and inhibins normally regulate diverse cellular functions such 
as cellular survival, proliferation and differentiation by binding to a heteromeric 
complex of type I and type II transmembrane serine/threonine kinase receptors 
(Figure 4). Signalling can be propogated via Smad-dependent and Smad-independent 
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pathways 
39
. In Smad-dependent pathways in which all 3 known HHT gene products 
function, ligand binding activates a TGF-β type II receptor which in turn 
phosphorylates and activates a type I receptor. The type I receptor subsequently 
phosphorylates and activates receptor associated (R)-Smads (Smads 1, 2, 3, 5, and/or 
8) which bind to Smad4 and translocate to the nucleus where they influence 
transcriptional activation with co-activators and co-repressors. Inhibitory Smads 
(Smad6/7) target R-Smads for degradation and provide a negative feedback loop for 
this pathway. In most cell types TβRII signalling transmits through ALK5 (TβRI) via 
the Smad2/3 pathway.  In endothelial cells however, TβRII signalling can also be 
propagated through ALK1 via the Smad1/5/8 pathway 
40
. The ALK1 ligand has been 
unknown for a long time but recently it was demonstrated that BMP9 and BMP10 are 
specific ALK1 ligands that, can also bind endoglin (Figure 4) 
41,42
.   
 
Several series of HHT animal models are now described.  Null mice for Eng and 
Acvrl1 die between E10.5-11.5 due to gross vascular and cardiac defects comparable 
to multiple other null mice, potentially reflecting aberrant placental vascular 
development.  Heterozygous mice develop variable but more HHT-specific features 
including nosebleeds, telangiectasia, dilated vessels and AVMs 
6,40
. Conditional LoxP 
knockout alleles have been generated for all three HHT genes, for ALK1 resulting in a 
model in which HHT-like vascular malformations occurred in a consistent and 
predictable manner 
43
.  These and other models are under active study. 
 
Current HHT models 
What causes the pathogenesis of HHT? This has been a controversial topic for many 
years and remains unresolved, in part due to the non-uniformity of the disease process 
in affected vascular beds.  The precise sequence of events remains to be determined 
 9 
but most likely involves aberrant endothelial cell responses to TGF-/BMP signalling 
in specific settings. 
A favored model has been generated from data focussing on the two TRII-associated 
type I receptors (ALK5 and ALK1), suggesting that the endothelial state depends on 
the predominant type I receptor utilised, and that abnormal vasculature in HHT 
resulted from a perturbation of this balance 
44
 
45
 
46
. This balance model has been both 
challenged 
43
, and supported 
47
 by recent data, and remains a helpful tool in clarifying 
signalling pathway inter-relationships. 
For example, endoglin and ALK1 are involved in angiogenesis, the process in which 
new blood vessels are formed from pre-existing ones. During angiogenesis, mural 
cells (smooth muscle cells; pericytes) detach, and brief periods of endothelial cell 
activation, proliferation and migration are co-ordinated with controlled proteolytic 
remodelling of the basement membrane and extracellular matrix, expression of 
endothelial cell survival factors, and recruitment of mural cells to stabilise the nascent 
blood vessels.  There are complex context-dependent biological activities of the HHT 
gene products in these processes such that over-expression of constitutively active 
ALK1, or under-expression of endoglin can each either promote or inhibit specific 
endothelial cell responses according to the experimental conditions.  However, 
evidence suggests that endoglin and ALK-1 responses promote opposing endothelial 
cell responses (such as proliferation; migration) to ALK5, and that the ratio of ALK5 
and ALK1 activation by TGF- superfamily ligands can influence whether pro or 
anti-angiogenic genes are predominantly expressed 
48
.  
 
 
MANAGEMENT 
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DIAGNOSTIC APPROACHES 
 
Clinical diagnosis of HHT 
The Curacao criteria, published in 2000 
49
, remain the mainstay of HHT clinical 
diagnosis. A definite diagnosis of HHT is made in the presence of at least three 
separate manifestions: 
 spontaneous recurrent nosebleeds; 
 mucocutaneous telangiectasia (multiple at characteristic sites: fingertip pulps, 
lips, oral mucosa, tongue); 
 visceral involvement (gastrointestinal, pulmonary, hepatic, cerebral or spinal 
AVM)  
 family history: a first degree relative affected according to these criteria  
 
Family history plus one criterion: When reviewing individuals from HHT families, 
clinicians are often faced with individuals with only one additional diagnostic 
criterion.  In clinical practice, if the non familial criterion is a visceral AVM which 
would be very rare in the general population, the diagnosis of HHT is essentially 
confirmed.  This is not the case for nosebleeds which are common in the general 
population, or non-florid telangiectasia which can be readily confused with non HHT 
pathologies.   For research and epidemiological studies, the labels of possible or 
suspected HHT should be used for all individuals with only two diagnostic criteria 
49
.   
 
Family history only:  While HHT is likely to present with nosebleeds during 
childhood, the condition cannot be excluded on clinical grounds even at the age of 30-
40 years .  For an apparently unaffected child of an HHT-affected parent, clinical data 
on age-related penetrance in European HHT populations allow estimations of the 
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probability of HHT-affected status ranging from 0.5 at 0 years; 0.22 at 16 years; 0.05 
at 40 years and 0.01 at 60 years 
21,50
 
51
. ‘Possible HHT’ can be added to the medical 
records of such individuals. 
 
 
Molecular diagnosis 
Genetic testing for endoglin, ACVRLI/ALK-1, and Smad4 is available and can confirm 
the diagnosis for the family, and confirm or refute the diagnosis in family members. 
Strategies to use genetic tests vary between units.  
 
For patients with definite clinical HHT, molecular testing is not required to confirm 
their diagnosis, but may assist management of other family members. Mutations are 
not found in about 20% of HHT families, hence failure to detect a causative HHT 
mutation in a family does not exclude HHT. Not all HHT gene sequence variations in 
HHT families are disease-causing (www.hhtmutation.org): where it is difficult to 
distinguish from incidental polymorphisms, assessment of co-segregation in a distant 
affected relative may be helpful. 
 
Genetic testing is most helpful in the settings of  
o a patient with suggestive but not confirmatory clinical features of HHT in 
which a positive test would be diagnostic; 
o a potentially unaffected family member in whom the diagnosis of HHT cannot 
be excluded clinically.    
 
Other genetic counselling  issues 
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o The hallmark of clinical HHT is the variability between different 
affected members of the same HHT family. Nevertheless there are 
genotype-phenotype correlations related to the causative HHT gene 
mutation, and as yet unidentified genetic modifiers 
o Prenatal diagnosis is technically feasible and chosen by some families.  
Generally however, there has been little interest in, or use of, prenatal 
molecular diagnosis for HHT in view of the longevity and pauci-
symptomatic state of most HHT patients^ (see Acknowledgements 
section).   
o A positive molecular diagnosis at present, does not modify 
recommended screening or management, except in the setting of HHT-
affected individuals with a family history of gastrointestinal 
polyps/malignancy: identification of a Smad4 mutation would lead to 
institution of gastrointestinal screening programmes. 
 
 
 
CLINICAL WORK UP 
The basic work up approach for suspected HHT patients is illustrated in Figure 5. 
Following a clinical evaluation including a detailed family history, emphasis is placed 
upon 
 ensuring that patients with a particular problem are reviewed by an organ-
specific specialist aware of HHT issues (details of management are beyond the 
scope of this text, but outlined within Table 2); 
 screening for asymptomatic AVMs according to local or regional practice (see 
below); 
 formalising the diagnosis of HHT which may require molecular testing; 
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 providing information and opportunity for follow up and family screens.   
 
Screening 
The medical justification for screening regimes in asymptomatic individuals from the 
HHT population centres on the degree of danger posed by silent AVMs (as opposed to 
symptomatic AVMs), the safety/tolerability of the diagnostic tool, the advantages 
offered by the correct diagnosis in term of patient management and follow up, and the 
safety of effective treatments. Risk-benefit evaluations are then performed to 
determine whether the detection and treatment of the asymptomatic AVM is likely to 
carry overall positive health benefits for the patient.   
 
Where risk benefit considerations are less clear cut, different interpretations are 
observed, and generally reflect the overall healthcare practices of particular countries 
and cultures.  In order to reflect these differing practices, and the evolving nature of 
recommendations as new data regarding natural history and treatment safety/ efficacy 
become available, Figure 5 presents only limited data regarding specific particular 
screening and management regimes.  Detailed considerations are presented below. 
 
Pulmonary AVMs 
Pulmonary AVMs are usually silent at the time of PAVM-induced strokes and brain 
abscess, can be diagnosed at low risk; and have an effective and safe treatment with 
embolisation shown to reduce or abolish neurological risks 
23
.  Hence detection and 
treatment of asymptomatic pulmonary AVMs is recommended worldwide for adults.   
 
For highly sensitive screening tests, the choice lies between thoracic CT scans and 
contrast echocardiography (CE).  Use of either test means that very few pulmonary 
PAVMs will be missed in an HHT population whereas chest x-rays, blood oxygen 
levels and right to left shunt measurements are insufficiently sensitive to exclude 
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pulmonary AVMs.  Both tests also allow for the detection of severe pulmonary 
hypertension which is a relative contraindication to embolisation 
52
. 
 
 
Many specialised units utilise a multistep screening programme using contrast 
echocardiography as a first line screen:  Following intravenous injection of contrast or 
microbubbles which should be removed by the normal pulmonary capillary bed, right 
to left shunting through pulmonary AVMs results in the appearance of microbubbles 
in the left side of the circulation.  Arrival is delayed compared to intracardiac shunts, 
with bubbles arriving after 3-10 cardiac cycles associated with pulmonary AVMs 
53
.  
Shunt severity may be graded by the number of microbubbles appearing on a single 
frame.   Higher grade shunts (>20-30 microbubbles per frame) have higher positive 
predictive values 
53
 
54,55
. Following a positive study, patients proceed to thoracic CT 
scans to determine anatomical features and suitability for embolisation treatment.  
 
Other institutions, including our own, do not used utilise CE routinely as the majority 
of studies are positive, and there are substantial time and resource implications. The 
new generations of CT scanners mean that a diagnosis of pulmonary AVMs can be 
made efficiently and quickly using a single thoracic CT scan which carries a radiation 
burden, but has the benefit of identifying additional pathology and embolisation 
contraindications, such as severe pulmonary hypertension. 
 
Discussion continues regarding the degree to which a negative screen (by CT or CE) 
can be used to rule out small PAVMs which may nevertheless carry risks of dental 
bacteraemias and decompression illness during scuba diving. Current practice at our 
institution is to provide recommendations regarding dental hygiene to all HHT 
patients, and to refer divers for specialist advice and evaluation.   
 15 
 
Cerebral AVMs:  
Screening of asymptomatic patients for cerebral AVMs is recommended in many 
countries but remains controversial in others^ : Cerebral haemorrhages in HHT 
patients are usually life-changing and may be fatal.  Conversely most HHT-related 
cerebral arteriovenous malformations will never bleed, and investigation and 
treatments carry risks.  Both sets of considerations differ with the precise anatomy and 
location of the AVM.  Other important considerations are that cerebral AVM are more 
common in HHT1 families 
35
 
34
 
30,33
 {Sabba, 2007 #39; Lesca, 2007 #38, and that the 
lifelong risk of haemorrhage is greater for younger patients due to their longer 
predicted lifespan.   
 
 In the UK, we have followed the interpretation articulated by the late Pierre 
Lasjaunias, that risk-benefit considerations for asymptomatic cerebral AVMs are 
usually not interpreted in favour of treatment because the risks of intervention are too 
high for the low risk of haemorrhage {Lasjaunias, 2007 #55}. Thus up to 10% of 
screened individuals would be faced with the identification of cerebral AVMs for 
which no treatment or management options would be recommended at the current 
time.  At our institution, we discuss these considerations openly with the patient and 
generally, cerebral MRI is not performed.  However, for any individual with a family 
member who has had a cerebral haemorrhage, or where there is any concern regarding 
cerebral symptoms, a cerebral MRI is recommended in order to rule out chance 
inheritance of familial aneurysms (which carry a higher risk of haemorrhage 
56
), or 
presence of an unstable, symptomatic cerebral AVM. 
 
Hepatic AVMs 
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Screening considerations for hepatic AVMs in asymptomatic individuals differ from 
those for cerebral and pulmonary AVMs since hepatic AVM management is directed 
towards symptomatic patients who receive intensive medical treatment, with liver 
transplantation (which is effective in HHT 
57
) reserved for non responders  
10
.
 
  
However, since there is a there is a totally non invasive and effective screeening tool 
(Doppler US), and because a correct diagnosis can help to clarify the diagnosis of 
HHT and improve subsequent patient management, screening of asymptomatic 
individuals for hepatic AVMs has been recommended 
10
.
 
 
 
Special considerations in pregnancy 
The overwhelming majority of pregnancies in women with HHT proceed normally, 
but there are small risks of life-threatening maternal complications: in a recent series 
of 484 pregnancies, 1.02% (95% confidence intervals 0.13, 1.92%) resulted in a major 
PAVM bleed; 1.24% (0.25, 2.23%) in stroke (not all were HHT-related); and 1.00% 
(0.13, 1.92%) in maternal death 
56
.  In British obstetric terminology, this renders HHT 
pregnancies high risk, for greater obstetric medical review than recommended for low 
risk pregnancies.  
 
The data for and against screening asymptomatic women during pregnancy for 
pulmonary, cerebral or spinal AVMs were discussed in detail in the paper 
56
.  The 
Anglo-French authors' recommendations for their obstetric healthcare systems were in 
the absence of symptoms, to defer pulmonary AVM screens, only perform cerebral 
imaging if warranted by family history, and to consider spinal MRI where the 
possibility of spinal AVMs would lead obstetric anaesthetists to withhold epidural 
analgesia.  There are strong opinions in other countries that asymptomatic women 
should be screened and treated for pulmonary AVMs during pregnancy.  As a result, 
there are different practices between countries.  
 17 
 
Children  
Occasional children from HHT families have major complications from HHT, but the 
majority most have healthy childhoods, with or without nosebleeds, and usually 
without anaemia.  AVMs may be present (cerebral AVMs usually develop perinatally 
and can bleed in childhood; pulmonary AVMs may develop in the pre pubertal period 
but complications in asymptomatic children must be extremely rare 
23
).  There are few 
data regarding dedicated risk-benefit considerations for the paediatric population, 
particularly concerning their increased susceptibility to diagnostic radiation-induced 
morbidity from CT scans 
58-60
 and angiography 
61
.  The ethics of screening an 
asymptomatic child, who is too young to give consent and will likely not understand 
the implications of testing, need also to be carefully be considered before proceeding 
Institutions therefore differ in their screening regimes.  Practice ranges from screening 
for all manifestations of HHT, to deferring screening in most asymptomatic children 
until post puberty unless dictated otherwise by family history.   
 
 
TREATMENT AND CARE 
Brief details of medical management are given in Table 2 for clinicians.  Additional 
information is warranted for several points for clinicians and patients alike.  Our 
practice is to provide this general advice for the whole family, with a particular focus 
for individual patients according to aspects of HHT known to affect them.  This is 
particularly important when the presence of HHT would modify general clinical 
protocols for management of common conditions such as stroke, and prophylaxis 
against deep venous thrombosis (see below) 
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Anaemia: It is unusual to be able to abolish nasal and gastrointestinal bleeding.  
Prevention and management of anaemia becomes paramount in at least a third of 
HHT patients.  Dietary advice for iron containing foods, and identification of oral 
iron preparations that suit the individual are important steps to reduce the need or 
frequency of transfusions or iron infusions required for severely affected 
individuals 
 
Pulmonary AVMs: Irrespective of size or symptoms, these carry risks of 
paradoxical embolic stroke and brain abscess which can be reduced or abolished 
by embolisation 
41
Due to brain abscesses links with dental microorganisms, 
scrupulous dental hygiene, and antibiotic prophylaxis at the time of dental 
procedures has been recommended, and this advice has been recently confirmed 
by senior British dentists, recognising the differences between HHT/PAVM 
patients, and individuals at risk of infective endocarditis for whom prophylaxis 
was withdrawn 
62
.   
 
Stroke advice: HHT-affected families should be aware in the event of stroke-like 
features, their doctors may need to be alerted to their three potential stroke types 
(haemorrhagic; ischaemic and brain abscess), leading to modification of local stroke 
management protocols. 
 
Liver evaluations: Hepatic AVMs commonly lead to asymptomatic abnormalities in 
biochemical markers of cholestasis, and the benign condition of focal nodular 
hyperplasia.  These are of little clinical importance but potentially could result in 
unnecessary diagnostic tests 
10
.  HHT patients should be advised to exclude liver 
biopsy unless imaging has excluded hepatic AVMs 
10
. 
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Deep venous thrombosis prophylaxis: Prophylaxis against deep venous thromboses 
is often modified or withheld for patients with haemorrhagic conditions such as HHT.  
Recent data highlight that HHT-affected individuals are at risk for thrombotic events, 
and should be considered for full prophylaxis at appropriate times, particularly in 
periods following a pulmonary AVM-induced brain abscess 
12
.  
 
Pregnancy:  Irrespective of prior screening and treatment, obstetricians should be 
alerted to the presence of HHT for all women with HHT.  Any haemoptysis or sudden 
severe dyspnoea should be considered a potential emergency prompting immediate 
hospital admission 
56
.  
 
 
CONCLUSION  
The diagnosis of HHT has been facilitated with the identification of several disease 
causing genes, but management of both symptomatic and asymptomatic individuals 
remains highly challenging for experienced specialists.  Discussion of risks and 
complex risk-benefit analyses need to be handled sensitively and appropriately for age, 
family, cultural and national background. Major clinical and research hurdles remain 
if we are to be able to more closely predict and prevent likely pathology in a condition 
in which the majority of individuals will not have major complications.  
 
  
SELF-HELP WEBSITES FOR HHT FAMILIES 
Country and language-specific information for HHT patients and families is available 
via a number of websites.  The EuroHHT Consortium plans an umbrella entry 
European website for 2009 (www.EuroHHT.com) 
   
Denmark www.osler.dk 
France  www.amro-france.org 
 20 
Germany  www.morbus-osler.de 
Ireland www.Gracenolan.com 
Italy   www.hht.it 
Netherlands www.renduoslerweber.nl 
Norway http://ssss.oslonett.no/side.php?mid=18&k=morbus_osler 
Spain  www.asociacionhht.org 
UK     www.telangiectasia.co.uk 
USA and international www.hht.org 
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LEGENDS TO FIGURES 
Figure 1: HHT images:  A) Fingertip and B) gastrointestinal telangiectasia (largest 
examples arrowed). C): 40X magnification of oral telangiectasis in individual with 
HHT compared to control (inset). Note thin wall denoted by arrow.  D). Pulmonary 
AVMs (arrowed) pre (i) and post(ii) embolisation: Angiograms courtesy of Dr James 
Jackson. 
 
Figure 2.  Circulatory explanation of HHT phenotypes.   
A) Schematic of systemic and pulmonary circulations demonstrating capillary beds in 
which HHT telangiectasia and AVMs occur. Note the pulmonary post capillary veins 
in direct communication with the left atrium, and portal vein (arrow) draining from 
gastrointestinal tract to liver acinus. 
B) Illustration of two separate pathologies resulting in severe pulmonary hypertension 
in two women with HHT (reported in 
63
). Note Case 1 has markedly elevated intrinsic 
pulmonary vascular resistance, whereas this is near- normal in Case 2 who has hepatic 
AVM-associated high output cardiac failure characterised by elevated cardiac output, 
cardiac index (not shown) and left atrial pressure. 
 
 
Figure 3: Schematic representations of HHT1-4.   
A: HHT1: Summary of 311 ENG mutations reported to www.hhtmut.org.  Note high 
proportion of out-of-frame mutations.   
B) HHT2: Summary of 250 ACVRL1 mutations reported to www.hhtmut.org.  Note 
higher frequency in exons 3, 7 and 8, and lower proportion of out-of-frame mutations.  
C) HHT3: 6 Mb HHT3 interval defined by key recombinants (black bars) between 
D5S2011 and D5S2490. Uninformative regions are shown in dashed bars 
27
. Ensembl 
predicts 29 genes in this interval.  
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D) HHT4:  7 Mb HHT4 interval between D7S2252 and D7S510 
28
, Ensembl predicts 
57 genes in this interval. Mb = mega base.  
 
Figure 4: TGF-β signalling pathway. Endoglin can interact with both type I and 
type II receptors. The genes mutated in HHT are highlighted in bold. 
 
Figure 5:  Schematic of management approaches. Similar principles operate 
throughout most HHT specialised services.  Further details are provided in the text. 
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Table 1:  
Table 1: HHT genes.  
 
HHT OMIM HHT type Chromosome Approved 
gene symbol 
Protein Sequence 
accession IDs 
Previous 
symbols 
Aliases 
HHT1 #187300 Type I 9 ENG Endoglin AF035753 ORW1, 
ORW 
HHT1, 
END, 
CD105 
HHT2 #600376 Type 2 12 ACVRL1 Activin 
receptor 
like kinase  
ALK-1 
L17075 ACVRLK1, 
ORW2 
HHT2, 
ALK1 
HTJP #175050 HTJP 18 SMAD4 Smad 4 NM 005359 MADH4 DPC4 
HHT3 %601101 Type 3 5       
HHT4 %610655 Type 4 7       
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Table 2: HHT Clinical features and management overview  
Feature % Haem. Other complications Management if symptomatic 
Curaçao Criteria 
Nasal 
telangiectasia 
 
90 
++++ 
Nosebleed
s 
  
Iron deficiency anaemia 
Iron +/- transfusions for anaemia.  
Nasal humidification; packing in emergencies. 
ENT: laser; surgery; embolisation;  
Systemic: oestrogen-progesterone, antifibrinolytics ±. 
Mucocutaneous 
telangiectasia 
 
80 ++   Laser or other ablation therapies  
Gastrointestinal 
telangiectasia 
20 +++ 
(chronic) 
 Iron deficiency anaemia Iron +/- transfusions  for anaemia. 
Gastroenterology: Repeated laser therapy; surgery or 
embolisation for emergency control 
Pulmonary 
AVMs 
50 + Right-to-left shunt: dyspnoea, 
stroke/ TIA; brain abscess; 
migraine; decompression illness 
Embolisation  
Dental hygiene and prophylactic antibiotics  
Caution against scuba diving 
Cerebral AVMs 10 ++ Space occupying lesion +/- 
vascular steal: headache, fit 
Cerebral MRI.  Refer to neurology for multidisciplinary 
evaluation of risk-benefits of treatment in an experienced 
centre 
Hepatic AVMs 3
0 
  Left to right shunt:  
high output cardiac heart failure; 
pulmonary hypertension.   
Hepato-portal shunt:  
portal hypertension.   
Porto-hepatic shunt:   
biliary ischaemia, encephalopathy  
Refer to specialised hepatology services for intensive 
medical management:  liver transplantation is the 
treatment of choice  if symptoms fail to respond to 
medical treatment 
10
 
  
Spinal AVMs <1 ++ Pain, asymmetric growth  Spinal MRI. Refer to neurology for multidisciplinary 
evaluation of risk-benefits of treatment in an experienced 
centre 
 30 
Non criterion manifestations 
Juvenile 
polyposis 
(Smad4) 
<1   Haemorrhage, malignancy Refer to Gastroenterology, and follow national 
surveillance guidelines such as 
11
 
Pulmonary 
hypertension  
<2   Dyspnoea, right heart failure Refer to Cardiorespiratory; Exclude hepatic AVMs; if 
present, consider liver transplant 
Prothrombotic 
state 
12
 
  Deep venous thrombosis, 
pulmonary emboli 
As per national guidelines eg  
13
 
Immune 
dysfunction 
14
 
  Uncertain  
 
Legend:. %: Estimated prevalence across all age groups.  Haem: haemorrhage frequency scale 0  to ++++. ± Ensure not prothrombotic first 
12
. Further agents are undergoing clinical evaluation, particularly in the setting of severe gastrointestinal and nasal haemorrhage.  Shunt 
anatomy: right-to-left: pulmonary artery to pulmonary vein, left-to-right: hepatic artery to hepatic vein, Hepato-portal: hepatic artery to 
portal vein; Porto-hepatic: portal vein to hepatic vein. * Recommended in Europe in certain circumstances (see text).  
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